Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Therapeutics, IncDEPO · Entity 149352 | SVP and CFO | July 16, 2018 | July 16, 2018 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | June 10, 2026 | June 13, 2026 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director | June 01, 2026 | June 02, 2026 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Therapeutics, Inc
Report date July 16, 2018 · Filed July 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 87,163 |
Reported balance
After 2018-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-16 · Grant · Acquired 87,163 · Balance 87,163 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2: These restricted stock units are scheduled to vest 33.33% on July 16, 2019, 33.33% on July 16, 2020 and 33.33% on July 16, 2021, assuming continued employment through the applicable vest period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
F2: These restricted stock units are scheduled to vest 33.33% on July 16, 2019, 33.33% on July 16, 2020 and 33.33% on July 16, 2021, assuming continued employment through the applicable vest period.
Faeth Therapeutics, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.41 · Expires 2036-06-09 | Direct | 12,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Taysha Gene Therapies, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 241,289 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 21,335 · Balance 241,289 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-01 | Direct | 42,671 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 42,671 · Balance 42,671 F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Tectonic Therapeutic, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08 | Direct | 10,200 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,800 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Acquired 3,800 · Balance 3,800 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.58 · Expires 2026-09-06 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.24 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 5,594 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.08 · Expires 2027-09-15 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 4,406 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.52 · Expires 2027-10-19 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 00:35 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001238120-26-000011 · form4-06132026_120629.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-06-09 F1 · kind: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 16:45 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 10,200 | $0.00 Strike: $28.56 | $0.00 |
DisclosureSEC source: 0001238120-26-000010 · form4-06102026_040603.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires 2036-06-08 F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 42,671 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001238120-26-000008 · form4-06022026_040614.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,671 Underlying: Common Stock · 42,671 shares Expires 2036-06-01 F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 21,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001238120-26-000008 · form4-06022026_040614.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,289 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 21:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 23,100 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0001238120-26-000006 · form4-04142026_090450.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,100 Underlying: Common Stock · 23,100 shares Expires 2036-04-09 F1 · kind: Represents a supplemental option grant to align the Reporting Person's total initial director option grant with the Company's non-employee director compensation policy, which was amended on April 10, 2026 to provide for an initial option grant of 25,000 shares to new directors. The Reporting Person previously received an initial grant of 1,900 shares in February 2026; this supplemental grant of 23,100 shares reflects the difference. F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or April 10, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0001238120-26-000004 · form4-02172026_100221.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,900 shares Expires 2036-02-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or February 13, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 16:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 10,200 | $0.00 Strike: $24.48 | $0.00 |
DisclosureSEC source: 0001415889-25-016676 · form4-06112025_040615.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires 2035-06-08 F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 113,246 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-25-015573 · form4-06042025_040607.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,246 Underlying: Common Stock · 113,246 shares Expires 2035-06-02 F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 56,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015573 · form4-06042025_040607.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,954 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:37 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 11,760 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017998 · form4-06242024_080629.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,760 Underlying: Common Stock · 11,760 shares Expires 2034-06-19 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option will vest on June 20, 2025, and the balance will vest in equal monthly installments thereafter over the next 24 months, subject in each case to the continuous service of the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 98,440 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015039 · form4-05312024_040505.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,440 Underlying: Common Stock · 98,440 shares Expires 2034-05-29 F2 · derivative.exercise_date: The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 49,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015039 · form4-05312024_040505.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,331 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:51 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 111,111 | $0.90 | $99,999.90 |
DisclosureSEC source: 0001209191-23-046148 · doc4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,111 Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:49 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 36,200 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-23-039731 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,200 Underlying: Common Stock · 36,200 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:30 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,643 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001127602-23-018290 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,643 Underlying: Common Stock · 17,643 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:40 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-038691 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:43 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017246 · form4.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:43 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017246 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 12:04 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 3,000 | $7.78 | $23,340.00 |
DisclosureSEC source: 0001209191-22-006641 · doc4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:05 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001209191-21-042112 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:04 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019804 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 19:06 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 2,000 | $11.71 | $23,420.00 |
DisclosureSEC source: 0001127602-21-006556 · form4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:09 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052112 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 17:15 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019024 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 17:09 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy · Derivative | 9,675 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-19-016854 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| July 16, 2018 Filed Jul 16, 2018 20:10 UTC | Assertio Therapeutics, Inc DEPO · Entity 149352 | GrantRestricted Stock Unit · Derivative | 87,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009699 · edgar.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,163 Underlying: Common Stock · 87,163 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: These restricted stock units are scheduled to vest 33.33% on July 16, 2019, 33.33% on July 16, 2020 and 33.33% on July 16, 2021, assuming continued employment through the applicable vest period. F2 · derivative.expiration_date: These restricted stock units are scheduled to vest 33.33% on July 16, 2019, 33.33% on July 16, 2020 and 33.33% on July 16, 2021, assuming continued employment through the applicable vest period. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:00 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017787 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,743 Underlying: Common Stock · 18,743 shares Expires 2028-06-20 F1 · derivative.exercise_date: The shares vest in 36 equal monthly installments following the closing of the Issuer's initial public offering. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · derivative · entry 6 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2028-03-13 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.52 | $0.00 |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · derivative · entry 5 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-10-19 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,406 | $0.00 Strike: $88.08 | $0.00 |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · derivative · entry 4 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,406 shares Expires 2027-09-15 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,594 | $0.00 Strike: $77.24 | $0.00 |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · derivative · entry 3 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,594 shares Expires 2027-05-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-09-06 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:29 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-030117 · doc4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 3,800 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:27 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-021777 · doc4.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-13 F2 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| March 13, 2018 Filed Mar 27, 2018 17:27 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021777 · doc4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
| October 19, 2017 Filed Oct 20, 2017 17:04 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.52 | $0.00 |
DisclosureSEC source: 0001209191-17-057658 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-10-18 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares underlying the option on October 19, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on November 19, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.